Physician–Patient Communication About Prescription Medication Nonadherence: A 50-state Study of America’s Seniors
- 685 Downloads
Understanding and improving the quality of medication management is particularly important in the context of the Medicare prescription drug benefit that took effect last January 2006.
To determine the prevalence of physician–patient dialogue about medication cost and medication adherence among elderly adults nationwide.
National stratified random sample of community-dwelling Medicare beneficiaries aged 65 and older.
Main Outcome Measures
Rates of physician–patient dialogue about nonadherence and cost-related medication switching.
Forty-one percent of seniors reported taking five or more prescription medications, and more than half has 2 or more prescribing physicians. Thirty-two percent overall and 24% of those with 3 or more chronic conditions reported not having talked with their doctor about all their different medicines in the last 12 months. Of seniors reporting skipping doses or stopping a medication because of side effects or perceived nonefficacy, 27% had not talked with a physician about it. Of those reporting cost-related nonadherence, 39% had not talked with a physician about it. Thirty-eight percent of those with cost-related nonadherence reported switching to a lower priced drug, and in a multivariable model, having had a discussion about drug cost was significantly associated with this switch (odds ratio [OR] 5.04, 95% confidence interval [CI] 4.28–5.93, P < .001).
We show that there is a communication gap between seniors and their physicians around prescription medications. This communication problem is an important quality and safety issue, and takes on added salience as physicians and patients confront new challenges associated with coverage under new Medicare prescription drug plans. Meeting these challenges will require that more attention be devoted to medication management during all clinical encounters.
Key wordsphysician–patient relations Medicare pharmaceutical services patient compliance
This research was supported the Commonwealth Fund and the Henry J. Kaiser Family Foundation. The authors gratefully acknowledge Spike Duzor, Maribel Franey, and Dural Suite (CMS) for their assistance with the authors’ data request. The contents of this paper are the sole responsibility of the authors and do not necessarily represent the views of the Commonwealth Fund, the Henry J. Kaiser Family Foundation, or Tufts–New England Medical Center.
Potential Financial Conflicts of Interest
- 2.Pear R. 17 Percent Increase in Prescription Drug Costs Hit Elderly Hardest, Study Finds. New York: The New York Times; 27 Jun 2000.Google Scholar
- 3.Strunk BC, Ginsburg PB, Gabel JR. Tracking health care costs. Health Aff. 2002;suppl:W39–W50.Google Scholar
- 4.Gross DJ, Schondelmeyer SW, Raetzman SO. Trends in manufacturer prices of brand name prescription drugs used by older Americans—first quarter 2004 update. Issue Brief (Public Policy Inst (Am Assoc Retired Pers)) 2004;(IB69):1–2.Google Scholar
- 10.Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: How well are states closing the gap. Health Aff (Millwood). 2002;W253–67.Google Scholar
- 15.Mays J, Brenner M, NeumanT CJCG. Estimates of Medicare Beneficiaries’ Out-of-pocket Drug Spending in 2006 (# 7201). Menlo Park, USA: Kaiser Family Foundation; 24 Nov 2004.Google Scholar
- 16.Kaiser Family Foundation. The Kaiser Family Foundation Health Poll Report Survey: Findings on the New Medicare Drug Law. Menlo Park, USA: Kaiser Family Foundation; 2005.Google Scholar
- 17.Kaiser Family Foundation. Seniors’ Early Experiences with the Medicare Prescription Drug Benefit—April 2006 (# 7501). Menlo Park, USA: Kaiser Family Foundation; 25 Apr 2006.Google Scholar
- 18.Dillman DA. Mail and Telephone Surveys: the Total Design Method. New York: John Wiley & Sons; 1978.Google Scholar
- 20.Buck SF. A method of estimation of missing values in multivariate data suitable for use with an electronic computer. J R Stat Soc. 1960;B22:302–6.Google Scholar
- 21.Rogers WH, Qian S, Kazis L. Imputing PCS and MCS in the Presence of Missing Data. Bedford, MA: Center for Health Quality, Outcomes, and Economic Research; 2003.Google Scholar
- 25.Safran DG, Neuman P, Schoen C, et al. Prescription Drug Coverage and Seniors: Findings From A 2003 National Survey. Health Aff (Millwood). 2005;24W5.152–66Google Scholar
- 26.Andersson K, Sonesson C, Petzold M, Carlsten A, Lonnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–8.PubMedCrossRefGoogle Scholar
- 29.U.S. Food and Drug Administration. FDA Assures Equivalence of Generic Drugs. USA: FDA; 2002.Google Scholar
- 32.Beney J, Bero LA, Bond C. Expanding the roles of outpatientpharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(3):CD000336.Google Scholar
- 34.Kaiser Family Foundation. The Transition of Dual Eligibles to Medicare Part D Prescription Drug Coverage (7467). Menlo Park, USA: Kaiser Family Foundation; 28 Feb 2006.Google Scholar
- 35.Pear R. Medicare Woes Take High Toll on Mentally Ill. New York: New York Times (online); 21 Jan 2006.Google Scholar
- 36.Berenson A. Drug Plan’s Side Effect is Severe. New York: New York Times (online); 8 Apr 2006.Google Scholar